The thesis

United Therapeutics operates in biotechnology with a gross margin of 8614.0% and a net margin of 4156.0%. The company's revenue growth is -1.9% YoY. The conviction score is 29/100, indicating a medium conviction tier. Analyst consensus rating is BUY, despite declining revenue growth.

Why now

The current macro context, with the S&P 500 and Nasdaq slipping due to inflation fears, may lead to a risk-off rotation. United Therapeutics' high margins and stable business model make it an interesting play in this environment.

What to watch

Investors should watch the company's revenue growth over the next quarter and the upcoming analyst ratings to confirm or deny the thesis. A change in the macro context, such as a shift in inflation expectations, could also impact the company's prospects.

Key risks

The key risks include valuation risk given the P/E ratio of 16.1x and DCF intrinsic value of $726, and execution risk due to declining revenue growth. A significant change in the competitive landscape or regulatory environment could also impact the company.

Theme exposure